Solid forms of nilotinib hydrochloride
US10016423B2 · kind B2 · utility
7Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 15, 2015 |
| Grant date | Jul 10, 2018 |
| Priority date | — |
| Expiry date | Oct 15, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A solid form of Nilotinib hydrochloride, which exists as a co-crystal of nilotinib hydrochloride and levulinic acid having a molar ratio of nilotinib hydrochloride to levulinic acid of 1:2, and a process for the preparation of the co-crystal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.